Open Orphan PLC - London-based pharmaceutical services - Signs a £6.2 million contract with an unnamed US-based biotech firm to test its antiviral candidate using the hVIVO influenza A human challenge study model.

The human challenge study is on-track to start in the second half of 2022, and revenue from the contract will be recognised across 2022 and 2023.

‘We are pleased to be working with this US-based client to test its exciting lead influenza antiviral using our Influenza human challenge study model. That the client has chosen us to run this study is testament to our position as the world leader in testing infectious and respiratory disease vaccines and antivirals using challenge studies,’ said Chief Executive Officer Yamin Khan.

Current stock price: 11.00 pence, up 7.3% on Thursday

12-month change: down 50%

Copyright 2022 Alliance News Limited. All Rights Reserved.